HGP0816
- Generic Name
- HGP0816
Evaluate the Pharmacokinetics and Safety of HCP1306 and Co-administration of HGP0816, HGP1404 in Healthy Male Volunteers
Phase 1
Completed
- Conditions
- Primary Hypercholesterolemia
- Interventions
- First Posted Date
- 2016-10-21
- Last Posted Date
- 2016-10-21
- Lead Sponsor
- Hanmi Pharmaceutical Company Limited
- Target Recruit Count
- 60
- Registration Number
- NCT02941848
Clinical Efficacy and Safety Evaluation of Co-administered HGP0904, HGP0608 and HGP0816 in Patients With Hypertension and Dyslipidemia
Phase 3
Completed
- Conditions
- HypertensionHyperlipidemia
- Interventions
- First Posted Date
- 2016-09-14
- Last Posted Date
- 2016-10-20
- Lead Sponsor
- Hanmi Pharmaceutical Company Limited
- Target Recruit Count
- 146
- Registration Number
- NCT02899455
- Locations
- π°π·
23 institutions including Samsung Medical Center, Seoul, Korea, Republic of
Evaluating a Pharmacokinetic Drug Interaction Between HGP0918 and HGP0816
- First Posted Date
- 2015-09-18
- Last Posted Date
- 2015-09-18
- Lead Sponsor
- Hanmi Pharmaceutical Company Limited
- Target Recruit Count
- 36
- Registration Number
- NCT02554136
- Locations
- π°π·
Inje Busan Paik hospital, Busan, Korea, Republic of
Evaluating the Efficacy and Safety of HCP1105 in Combined Hyperlipidemic Patients With High Risk for CHD
Phase 3
- Conditions
- Hyperlipidemias
- Interventions
- First Posted Date
- 2015-09-16
- Last Posted Date
- 2015-09-16
- Lead Sponsor
- Hanmi Pharmaceutical Company Limited
- Target Recruit Count
- 270
- Registration Number
- NCT02551172
- Locations
- π°π·
Euljii General Hospital, Seoul, Korea, Republic of
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
Β© Copyright 2025. All Rights Reserved by MedPath